Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
23.27
+0.16 (+0.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes
January 08, 2024
Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco.
Via
Investor's Business Daily
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
January 07, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
January 02, 2024
From
Exelixis, Inc.
Via
Business Wire
NASDAQ:EXEL is showing good growth, while it is not too expensive.
December 21, 2023
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
6 Analysts Have This to Say About Exelixis
December 13, 2023
Via
Benzinga
NASDAQ:EXEL, a growth stock which is not overvalued.
November 29, 2023
Investors seeking growth at a reasonable cost should explore NASDAQ:EXEL.
Via
Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:EXEL.
November 06, 2023
EXELIXIS INC (NASDAQ:EXEL) is showing decent growth, but is still valued reasonably.
Via
Chartmill
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
December 07, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
December 04, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
December 04, 2023
From
Arcus Biosciences
Via
Business Wire
Where Exelixis Stands With Analysts
November 02, 2023
Via
Benzinga
Earnings Outlook For Exelixis
October 31, 2023
Via
Benzinga
Is Exelixis Stock a Buy Now?
October 18, 2023
There is one key reason to consider the stock.
Via
The Motley Fool
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
November 29, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
November 21, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
November 10, 2023
From
Exelixis, Inc.
Via
Business Wire
14 Analysts Have This to Say About Exelixis
October 11, 2023
Via
Benzinga
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
November 09, 2023
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.
Via
InvestorPlace
3 Biotech Stocks With the Strongest Clinical Pipelines
November 08, 2023
Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.
Via
InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Via
InvestorPlace
Exelixis (EXEL) Q3 2023 Earnings Call Transcript
November 02, 2023
EXEL earnings call for the period ending September 30, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 01, 2023
From
Exelixis, Inc.
Via
Business Wire
4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
October 28, 2023
Bargains abound for growth-seeking investors, with the Nasdaq Composite still 20% below its record-closing high.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
October 25, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Why Exelixis Stock Is Trading Lower Today
October 23, 2023
Exelixis, Inc. (NASDAQ: EXEL) shares are trading lower on Monday after the company announced detailed results from its Phase 3 CABINET pivotal trial evaluating Cabozantinib in
Via
Benzinga
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
October 22, 2023
From
Exelixis, Inc.
Via
Business Wire
3 Under-the-Radar Biotech Stocks to Buy in 2023
October 19, 2023
These three lesser-known biotech companies are profitable and growing revenue.
Via
The Motley Fool
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
October 18, 2023
From
Exelixis, Inc.
Via
Business Wire
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
October 13, 2023
EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive.
Via
Chartmill
Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains
October 02, 2023
Low-beta stocks provide an avenue for investors looking for long-term growth accompanied by low volatility.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.